HBK Sorce Advisory LLC bought a new position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 49,844 shares of the biotechnology company's stock, valued at approximately $473,000. HBK Sorce Advisory LLC owned 0.11% of Capricor Therapeutics at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Oppenheimer & Co. Inc. boosted its stake in Capricor Therapeutics by 24.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 129,195 shares of the biotechnology company's stock worth $1,226,000 after acquiring an additional 24,964 shares during the last quarter. Krilogy Financial LLC raised its holdings in Capricor Therapeutics by 9.6% in the first quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company's stock worth $216,000 after purchasing an additional 2,000 shares during the period. Rhumbline Advisers boosted its position in shares of Capricor Therapeutics by 8.1% during the first quarter. Rhumbline Advisers now owns 49,814 shares of the biotechnology company's stock worth $473,000 after purchasing an additional 3,731 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Capricor Therapeutics during the fourth quarter worth $565,000. Finally, California State Teachers Retirement System grew its holdings in shares of Capricor Therapeutics by 1,653.0% in the 4th quarter. California State Teachers Retirement System now owns 32,237 shares of the biotechnology company's stock valued at $445,000 after buying an additional 30,398 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Oppenheimer lowered their price target on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a report on Monday. B. Riley initiated coverage on Capricor Therapeutics in a research report on Thursday. They set a "buy" rating and a $21.00 price target on the stock. Roth Capital reiterated a "buy" rating and issued a $31.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, June 17th. Finally, Wall Street Zen cut Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $33.75.
Get Our Latest Report on CAPR
Capricor Therapeutics Price Performance
CAPR stock opened at $10.18 on Friday. The stock has a market capitalization of $465.02 million, a P/E ratio of -7.17 and a beta of 0.84. Capricor Therapeutics, Inc. has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The business has a 50-day moving average of $10.89 and a 200-day moving average of $12.38.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same quarter in the previous year, the firm posted ($0.31) EPS. Equities analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.
Capricor Therapeutics Profile
(
Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Want to see what other hedge funds are holding CAPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
